Ritlecitinib and Baricitinib Show Comparable Efficacy in Severe Alopecia Areata
Based on the most recent real-world evidence, ritlecitinib 50 mg and baricitinib 4 mg demonstrate essentially equivalent success rates in severe alopecia areata, with approximately 60-65% of patients achieving SALT ≤20 (≥80% scalp coverage) at 52 weeks 1.
Direct Comparative Evidence
The highest quality comparative data comes from a 2026 monocentric retrospective study that directly evaluated both agents in routine clinical practice 1. This real-world study provides the most relevant evidence for treatment decision-making:
Success Rates at Key Timepoints
Week 16 Response (SALT ≤20):
- Baricitinib 4 mg: 39.6%
- Ritlecitinib 50 mg: 36.8%
Week 52 Response (SALT ≤20) - Primary Endpoint:
- Baricitinib 4 mg: 65.5%
- Ritlecitinib 4 mg: 61.5%
These differences are clinically negligible, indicating comparable effectiveness 1.
Eyebrow and Eyelash Regrowth
For patients with baseline eyebrow/eyelash involvement (ClinRO ≥2):
Eyelash response at Week 52:
- Baricitinib: 63.0%
- Ritlecitinib: 60.0%
Eyebrow response at Week 52:
- Baricitinib: 59.4%
- Ritlecitinib: 40.0%
Baricitinib showed numerically better eyebrow regrowth, though both agents demonstrated meaningful improvement 1.
Supporting Evidence from Indirect Comparisons
A 2025 systematic review with Bayesian network meta-analysis found no statistically significant difference between ritlecitinib 50 mg and baricitinib 4 mg at Week 24 for either SALT ≤10 (OR: 0.96,95% CrI: 0.18-7.21) or SALT ≤20 (OR: 2.16,95% CrI: 0.48-16.46) 2. This analysis adjusted for potential effect modifiers including sex, baseline SALT score, and disease duration, confirming comparable efficacy.
Safety Profile Differences
Baricitinib 4 mg:
- Non-severe adverse events: 42.7%
- Most common: weight gain, upper respiratory infections, acne, hyperlipidemia
- Discontinuation due to AEs: 3.6%
- No major cardiovascular, thromboembolic, or malignancy events 1
Ritlecitinib 50 mg:
- Non-severe adverse events: 26.0% (significantly lower)
- Discontinuation due to AEs: 3.1%
- Generally better tolerated with fewer metabolic side effects 1
Treatment Duration Considerations
For severe AA (SALT 50-94):
- 70% achieve SALT30 by Week 24 with short disease duration
- 75% reach SALT ≤20 by Week 52
- Assess treatment response at 24 weeks 3
For very severe AA (SALT 95-100):
- Only 25-42% achieve SALT30 by Week 24
- Continue treatment for at least 52 weeks before declaring failure
- Response continues to accrue through Week 52 3
Predictors of Response
Real-world data from baricitinib treatment identified two independent predictors of Week 36 response 4:
- Disease duration <2 years (p <0.05)
- Baseline eyebrow loss (ClinRO score 3) (p <0.05)
These factors likely apply to both JAK inhibitors given their similar mechanisms.
Critical Treatment Considerations
Relapse Risk After Discontinuation:
- 100% of responders who discontinued baricitinib relapsed (mean 14.7 weeks)
- Among patients reducing dose to 2 mg daily: 50% relapsed (mean 24.2 weeks)
- Monitor closely for 3 months after discontinuation and 6 months after dose reduction 4
Cost-Effectiveness: At Week 52, ritlecitinib demonstrated lower cost per responder ($94,834) compared to baricitinib ($107,217), though both agents showed favorable cost-effectiveness profiles 5.
Clinical Decision Algorithm
Choose either agent based on:
Patient preference for side effect profile:
- Prefer ritlecitinib if concerned about weight gain or metabolic effects
- Either agent acceptable if metabolic monitoring feasible
Disease characteristics:
- Both equally effective regardless of severity
- Consider longer trial (52 weeks) for SALT 95-100
Formulary/insurance considerations:
- Both FDA-approved for severe AA
- Select based on coverage and cost-sharing
Treatment goals:
- For eyebrow regrowth specifically: slight numerical advantage with baricitinib
- For scalp and eyelash: equivalent outcomes
Important Caveats
The available guidelines 6 predate JAK inhibitor approval (2012) and therefore do not address these agents. The FDA label for baricitinib 7 confirms approval for severe AA but does not provide comparative data with ritlecitinib. Treatment decisions must rely on recent clinical trial and real-world evidence rather than outdated guidelines.
Both agents require long-term therapy to maintain response, and discontinuation commonly leads to relapse. Set realistic expectations with patients about treatment duration (minimum 6-12 months) and the likely need for indefinite therapy to sustain hair regrowth.